As promised, the restructuring initiatives taking place at Charles River Labs (NYSE: CRL) have resulted in a reduced headcount at the contract research organization.

Charles River Laboratories, the largest corporate recipient of NIH funding in Mass., is not overly concerned with the political turmoil over federal scientific funding, but is facing another political headwind: a potential disruption to its monkey business.